Physician profile
Thomas E Diggs
NPI 1962418889
$5,084.94
in general payments reported to CMS, 2019-2025
32 companies · $961 in 2025
The $961 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $329 · 2021: $794 · 2022: $953 · 2023: $698 · 2024: $453 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,112.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $585.32 | 2019-2025 | |
| Aop Health US, LLC | $475.50 | 2025 | Rapiblyk |
| Pfizer INC. | $473.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $425.09 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $384.84 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $294.21 | 2019-2024 | Mitraclip |
| Merck Sharp & Dohme LLC | $268.70 | 2021-2023 | Verquvo |
| Philips North America LLC | $226.51 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $216.78 | 2019-2023 | Lifevest |
| Astellas Pharma US INC | $216.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $213.57 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $203.28 | 2019-2025 | Wainua, Andexxa |
| Cvrx, INC. | $194.65 | 2021-2023 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $119.96 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $88.56 | 2019-2023 | Opsumit, Uptravi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $81.35 | 2019-2023 | Evkeeza |
| Medtronic, INC. | $70.70 | 2025 | Micra, Aurora Ev-Icd Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.61 | 2021-2023 | Jardiance |
| Zoll Circulation INC | $67.62 | 2020 | |
| Sanofi-Aventis U.S. LLC | $61.25 | 2019 | |
| Boston Scientific Corporation | $41.87 | 2024-2025 | Lux-Dx Insertable Cardiac Monitor |
| Cleerly, INC. | $38.75 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Kiniksa Pharmaceuticals, Ltd. | $37.95 | 2021-2022 | |
| Teleflex LLC | $36.06 | 2023 | Quikclot |
| Abiomed | $32.62 | 2022 | |
| Novo Nordisk INC | $31.07 | 2025 | Rybelsus, Ozempic |
| Itamar Medical INC | $26.61 | 2022-2025 | Watchpatone |
| Kiniksa Pharmaceuticals International, Plc | $26.16 | 2024 | Arcalyst |
| Chiesi USA, INC. | $20.86 | 2022 | |
| Medtronic Vascular, INC. | $19.14 | 2020 | |
| Scpharmaceuticals INC. | $19.10 | 2023 | |
| Esperion Therapeutics, INC. | $17.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Diggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.